Is Cold Storage Still a Must? Evaluating Room-Temperature OnabotulinumtoxinA for Glabellar Lines Treatment.
Abstract
[BACKGROUND] New botulinum toxin type A (BoNT-A) formulations eliminated cold-chain storage before reconstitution. Nonetheless, concerns remain about BoNT-A properties when stored at room temperature after reconstitution.
[AIM] This study aimed to evaluate the sterility and effectiveness of BoNT-A storage at room temperature in glabellar wrinkles.
[METHODS] BoNT-A (Allergan Botox, Brazil) was reconstituted and maintained in a stove at 37°C for 60 days and then tested for sterility according to the Pharmacopeia guidelines. Then, sixty patients aged 25-60 years were divided into two groups: Group 1 (G1) received BoNT-A immediately after reconstitution, and Group 2 (G2) received BoNT-A after 7 days at room temperature. Participants were assessed for wrinkle severity using the Merz Scale, satisfaction with treatment using the Face-Q scale, and muscle activity by electromyography. Data were collected before injections and after 15, 30, 60, and 90 days.
[RESULTS] Absence of turbidity evidenced no microbial growth in all periods analyzed. Both groups showed significant reductions in glabellar contraction (p < 0.001), wrinkle severity (p < 0.05), and improved satisfaction. G1 presented lower wrinkle severity, while G2 reported higher satisfaction (p < 0.05).
[CONCLUSION] Room temperature and longer storage periods may not affect OnabotulinumtoxinA sterility and clinical results.
[AIM] This study aimed to evaluate the sterility and effectiveness of BoNT-A storage at room temperature in glabellar wrinkles.
[METHODS] BoNT-A (Allergan Botox, Brazil) was reconstituted and maintained in a stove at 37°C for 60 days and then tested for sterility according to the Pharmacopeia guidelines. Then, sixty patients aged 25-60 years were divided into two groups: Group 1 (G1) received BoNT-A immediately after reconstitution, and Group 2 (G2) received BoNT-A after 7 days at room temperature. Participants were assessed for wrinkle severity using the Merz Scale, satisfaction with treatment using the Face-Q scale, and muscle activity by electromyography. Data were collected before injections and after 15, 30, 60, and 90 days.
[RESULTS] Absence of turbidity evidenced no microbial growth in all periods analyzed. Both groups showed significant reductions in glabellar contraction (p < 0.001), wrinkle severity (p < 0.05), and improved satisfaction. G1 presented lower wrinkle severity, while G2 reported higher satisfaction (p < 0.05).
[CONCLUSION] Room temperature and longer storage periods may not affect OnabotulinumtoxinA sterility and clinical results.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 1 | |
| 시술 | botox
|
보툴리눔독소 주사 | dict | 1 | |
| 해부 | Glabellar Lines
|
scispacy | 1 | ||
| 해부 | muscle
|
scispacy | 1 | ||
| 해부 | glabellar
|
scispacy | 1 | ||
| 합병증 | glabellar wrinkles
|
scispacy | 1 | ||
| 합병증 | wrinkle
|
scispacy | 1 | ||
| 약물 | OnabotulinumtoxinA
|
scispacy | 1 | ||
| 약물 | [BACKGROUND] New botulinum toxin type A
|
scispacy | 1 | ||
| 약물 | BoNT-A
→ botulinum toxin type A
|
scispacy | 1 | ||
| 질환 | reductions in glabellar contraction
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | Face-Q
|
scispacy | 1 |
MeSH Terms
Humans; Botulinum Toxins, Type A; Skin Aging; Adult; Middle Aged; Female; Drug Storage; Patient Satisfaction; Neuromuscular Agents; Forehead; Male; Time Factors; Cold Temperature; Treatment Outcome; Temperature
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.